RxDoctor Payments Data

Rama Kethineni

Nephrology · Fayetteville, NCNPI 1417226721

Payments from drug & device makers

$1,605in general payments, 2019–2025

Across 69 payments — averaging $23.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$343
  • Otsuka America Pharmaceutical, Inc.$203
  • Aurinia Pharma U.S., Inc.$175
  • Amgen$164
  • Actelion Pharmaceuticals US, Inc.$125
  • Calliditas Therapeutics US Inc.$111
  • plus $484 from 11 others

What the payments were for

  • Food & beverage$1,58299%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,605 in reported general payments places this provider in the 50th percentile of 366 nephrology providers in North Carolina.

See all nephrology providers in North Carolina

Medicare billing

Part B allowed, 2024
$136,981
Medicare patients
386
Services billed
1,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol33$30,699
JardianceEmpagliflozin11$15,735
Sevelamer Carbonate39$6,107
Calcium Acetate44$2,063
Torsemide78$1,397
Losartan Potassium111$917
Nifedipine ErNifedipine23$849
Potassium Chloride18$656
Calcitriol28$356
Chlorthalidone11$241
Midodrine Hcl13$189
Hydralazine Hcl15$181
Carvedilol22$161
Spironolactone15$148
Amlodipine Besylate26$126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$343$30,69933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 366 nephrology providers in North Carolina.

Other nephrology in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →